BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-438 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-438\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07409246-3190@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:ABBV-438: Phase 1 readout est. (NCT07409246)
DESCRIPTION:ABBV-438\, phase 1\, Multiple Myeloma.\nStudy: A Study to Evalu
 ate Adverse Events\, Change in Disease Activity\, Tolerability\, and How I
 ntravenous ABBV-438 Moves Through the Body in Adult Participants With Mult
 iple Myeloma (MM)\nEstimated primary completion: November 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/abbv-438#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07409246
URL:https://assetmemo.bio/drug/abbv-438#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
